Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - hydroxide polymaltose complex eqv iron - syrup - 10mg/ml - hydroxide polymaltose complex eqv iron 50mg/5ml

Malta - English - Medicines Authority

wallace manufacturing chemists limited - dimethicone, activated, aluminium hydroxide, magnesium hydroxide - oral suspension - dimethicone, activated 25 milligram(s) ; aluminium hydroxide 220 milligram(s) ; magnesium hydroxide 200 milligram(s) - drugs for functional gastrointestinal disorders

Singapore - English - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - iron hydroxide polymaltose eqv iron - solution - 50 mg/ml - iron hydroxide polymaltose eqv iron 50 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rupatadine fumarate - oral tablet - 10mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 169.72mg equivalent to venlafaxine 150 mg;  ;  ;   - modified release tablet - 150 mg - active: venlafaxine hydrochloride 169.72mg equivalent to venlafaxine 150 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 254.58mg equivalent to venlafaxine 225 mg;  ;  ;   - modified release tablet - 225 mg - active: venlafaxine hydrochloride 254.58mg equivalent to venlafaxine 225 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 42.43mg equivalent to venlafaxine 37.5 mg;  ;  ;   - modified release tablet - 37.5 mg - active: venlafaxine hydrochloride 42.43mg equivalent to venlafaxine 37.5 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - venlafaxine hydrochloride 84.86mg equivalent to venlafaxine 75 mg;  ;  ;   - modified release tablet - 75 mg - active: venlafaxine hydrochloride 84.86mg equivalent to venlafaxine 75 mg       excipient: cellulose acetate colloidal silicon dioxide cellulose acetate 398-10 nf macrogol 400   magnesium stearate mannitol microcrystalline cellulose opadry white y-30-18037 povidone - · arrow – venlafaxine xr is indicated for the treatment of major depression. arrow – venlafaxine xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg;  ;  ;  ; venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg; venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg - modified release capsule - 150 mg - active: venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg       excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer erythrosine ethanol gelatin hypromellose indigo carmine isopropyl alcohol magnesium stearate sodium laurilsulfate titanium dioxide active: venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer erythrosine ethanol gelatin hypromellose indigo carmine isopropyl alcohol magnesium stearate sodium laurilsulfate titanium dioxide active: venlafaxine hydrochloride 169.71mg equivalent to venlafaxine 150 mg excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer erythrosine ethanol gelatin hypromellose indigo carmine isopropyl alcohol magnesium stearate opacode black s-1-17823 sodium laurilsulfate titanium dioxide - adults enlafax-xr is indicated for the treatment of: - major depression - generalised anxiety disorder - social anxiety disorder - panic disorder. enlafax-xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine;  ;  ;  ; venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine; venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine - modified release capsule - 37.5 mg - active: venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine       excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer ethanol gelatin hypromellose isopropyl alcohol magnesium stearate sodium laurilsulfate titanium dioxide active: venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer ethanol gelatin hypromellose isopropyl alcohol magnesium stearate sodium laurilsulfate titanium dioxide active: venlafaxine hydrochloride 42.43mg equivalent to 37.5 mg venlafaxine excipient: acetone ammonio methacrylate copolymer basic butylated methacrylate copolymer ethanol gelatin hypromellose isopropyl alcohol magnesium stearate opacode black s-1-17823 sodium laurilsulfate titanium dioxide - adults enlafax-xr is indicated for the treatment of: - major depression - generalised anxiety disorder - social anxiety disorder - panic disorder. enlafax-xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.